報價延遲最少15分鐘:2025/07/15 17:45 EDT
盤後時段
|
||||
|
1.2601 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.3
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.77/-0.85
|
|
企業價值
80.44M
|
| 資產負債 |
|
每股賬面淨值
2.23
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/07/15 17:45 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases. |
